1. Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 2006; 39 (Suppl 1): S10-4.
2.
Chen JJ. Treatment of psychotic symptoms in patients with Parkinson disease. The mental health clinician 2018; 7 (6): 262-270.
3.
Chinta SJ, Andersen JK. Dopaminergic neurons. The international journal of biochemistry & cel biology 2005; 37 (5): 942-6.
4.
Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clinical pharmacokinetics 2005; 41 (4): 261-309.
5.
de Sousa Moreira JL, Barbosa SMB, Vieira JG, Chaves NCB, Felix EBG, Feitosa PWG, et al. The psychiatric and neuropsychiatric repercussions associated with severe infections of COVID-19 and other coronaviruses. Progress in neuro-psychopharmacology & biological psychiatry 2021; 106: 110159.
6.
deVries T, Dentiste A, Di Lea C, Pichette V, Jacobs D. Effects of renal impairment on the pharmacokinetics of once-daily amantadine extended-release tablets. CNS Drugs 2019; 33 (8): 783-789.
7.
Fryml LD, Williams KR, Pelic CG, Fox J, Sahlem G, Robert S, et al. The role of amantadine withdrawal in 3 cases of treatment-refractory altered mental status. Journal of psychiatric practice 2017; 23 (3): 191-199.
8.
Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 2012, 78 (14): 1096-9.
9.
Krzystanek M, Pałasz A. Possibility of a new indication for amantadine in the treatment of bipolar depression-case series study. Pharmaceuticals (Basel, Switzerland) 2020, 13 (10): 326.
10.
Krzystanek M, Warchala A, Trędzbor B, Martyniak E, Skałacka K, Pałasz A. Amantadine in the treatment of sexual inactivity in schizophrenia patients taking atypical antipsychotics – the pilot case series study. Pharmaceuticals (Basel, Switzerland) 2021, 14 (10): 947.
11.
Liu P, Cheng PJ, Ing TS, Daugirdas JT, Jeevanandhan R, Soung LS, et al. In vitro binding of amantadine to plasma proteins. Clinical Neuropharmacology 1984; 7 (2): 149-51.
12.
Ly D, DeLisi LE. Can antibiotics cause a psychosis?: Case report and review of the literature. Schizophrenia research 2017; 189: 204-207.
13.
Marxreiter F, Winkler J, Uhl M, Madżar D. A case report of severe delirium after amantadine withdrawal. Case reports in neurology 2017; 9 (1): 44-48.
14.
Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. The Journal of neuroscience: the official journal of the Society for Neuroscience 1997; 17 (8): 2921-7.
15.
Newcomer JW, Farber NB, Olney JW. NMDA receptor function, memory, and brain aging. Dialogues in clinical neuroscience 2000; 2 (3): 219-32.
16.
Raupp-Barcaro IF, Vital MA, Galduróz JC, Andreatini R. Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials. Revista brasileira de psiquiatria 2018; 40 (4): 449-458.
17.
Rosner MH, Husain-Syed F, Reis T, Ronco C, Vanholder R, 2022. Uremic encephalopathy. Kidney international 2022; 101 (2): 227-241.
18.
Sławek J. Kliniczne znaczenie blokowania receptora NMDA. Polski przegląd Neurologiczny 2013; 9: 39-46.
19.
Soung LS, Ing TS, Daugirdas JT, Wu MJ, Gandhi VC, Ivanovich PT, et al. Amantadine hydrochloride pharmacokinetics in hemodialysis patients. Annals of internal medicine 1980; 93 (1): 46-9.
20.
Wilcox JA, Tsuang J. Psychological effects of amantadine on psychotic subjects. Neuropsychobiology 1990; 23 (3): 144-6.
21.
Xu WJ, Wei N, Xu Y, Hu SH. Does amantadine induce acute psychosis? A case report and literature review. Neuropsychiatric disease and treatment 2016; 12: 781-3.
